Contrasting Uniqure (QURE) and Reata Pharmaceuticals (RETA)
Uniqure (NASDAQ: QURE) and Reata Pharmaceuticals (NASDAQ:RETA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.
Institutional & Insider Ownership
25.0% of Uniqure shares are held by institutional investors. Comparatively, 29.5% of Reata Pharmaceuticals shares are held by institutional investors. 0.7% of Uniqure shares are held by insiders. Comparatively, 44.0% of Reata Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Uniqure and Reata Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and recommmendations for Uniqure and Reata Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Uniqure currently has a consensus target price of $19.86, indicating a potential upside of 2.36%. Reata Pharmaceuticals has a consensus target price of $54.71, indicating a potential upside of 103.70%. Given Reata Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Reata Pharmaceuticals is more favorable than Uniqure.
Valuation and Earnings
This table compares Uniqure and Reata Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Uniqure||$25.10 million||23.81||-$73.37 million||($2.61)||-7.43|
|Reata Pharmaceuticals||$49.86 million||14.07||-$6.22 million||($1.46)||-18.40|
Reata Pharmaceuticals has higher revenue and earnings than Uniqure. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than Uniqure, indicating that it is currently the more affordable of the two stocks.
Reata Pharmaceuticals beats Uniqure on 11 of the 13 factors compared between the two stocks.
Uniqure Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company’s product candidates within the Core Program include AMT-061 for Hemophilia B, AMT-130 for Huntington’s disease and S100A1 for congestive heart failure. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich’s ataxia, mitochondrial myopathies and metastatic melanoma.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.